Updates to the NCCN's Guidelines for Non-Hodgkin's Lymphoma

Updates and recommendations have been made to the National Comprehensive Cancer Network's (NCCN) Clinical Practice Guidelines in Oncology. These updates were presented at the recent NCCN Annual Conference. The most important updates are outlined below regarding non-Hodgkin's lymphoma by Steven M. Horowitz MD, of Memorial Sloan Kettering Cancer Center by way of Onclive.

Chronic Lymphocytic Leukemia: For patients with previously untreated chronic lymphocytic leukemia (CLL), obinutuzumab (Gazyva) plus chlorambucil has been added as a therapy option for patients without an 11q or 17p deletion who might be "frail with significant comorbidities, and both older and younger patients either with or without comorbidities."

Chronic Lymphocytic Leukemia: Imbruvica (ibrutinib) has also been added as a therapy option for patients with CLL without an 11q or 17p deletion who have received at least one prior therapy.

Diffuse Large B-cell Lymphoma (DLBCL): Recommended follow-up imaging post-treatment has been changed from CT scans every 6 months to 2 years to "only as clinically needed."

Follicular Lymphoma: The NCCN now recommends PET-CT scans for evaluation at presentation and following initial response to front-line therapy.

Perhaps most interestingly, a pair of new guidelines for rare lymphomas have been added. The new guidelines are characterized as "largely educational to define these diseases and help clinicians accurately recognize and distinguish [them] from other types of lymphomas", and they are for:

  • Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorder
  • T-Cell Large Granular Lymphocyte Leukemia

Source: OncLive

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap